S100A11 (calgizzarin) is released by circulating mononuclear
cells and its elevated plasma levels distinguish systemic lupus
erythematosus patients from healthy individuals

J 2019

S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals

CEREZO, L. A., B. SUMOVA, H. HULEJOVA, H. STORKANOVA, Lenka SZCZUKOVÁ et. al.

Základní údaje

Originální název

S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals

Autoři

CEREZO, L. A. (203 Česká republika), B. SUMOVA (203 Česká republika), H. HULEJOVA (203 Česká republika), H. STORKANOVA (203 Česká republika), Lenka SZCZUKOVÁ (203 Česká republika, domácí), M. TOMCIK (203 Česká republika), R. BECVAR (203 Česká republika), K. PAVELKA (203 Česká republika), J. VENCOVSKY (203 Česká republika), J. ZAVADA (203 Česká republika) a L. SENOLT (203 Česká republika, garant)

Vydání

Clinical and Experimental Rheumatology, PISA, CLINICAL & EXPER RHEUMATOLOGY, 2019, 0392-856X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30226 Rheumatology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.319

Kód RIV

RIV/00216224:14110/19:00112790

Organizační jednotka

Lékařská fakulta

UT WoS

000461612600024

Klíčová slova anglicky

S100A11; mononuclear cells; systemic lupus erythematosus

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2020 10:50, Mgr. Tereza Miškechová

Anotace

V originále

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with complex immunological pathogenesis and diverse clinical features, as a consequence of multi-system inflammation (1). Although there has been a significant progress in the management of patients with SLE, there is an unmet need for specific diagnostic or predictive biomarkers for routine clinical use. Certain members of S100 protein family such as S100A8/9 and S100A12 are upregulated in several autoimmune inflammatory disorders, including SLE (2-4), and their potential as diagnostic or prognostic biomarkers is emerging. S100A11 (calgizzarin) is a less known S100 protein that has been extensively studied in cancer (5). Very recently, our group showed an implication of S100A11 in the pathogenesis of rheumatoid arthritis (RA) and thereby its potential role in autoimmune diseases (6). We described a local accumulation of S100A11 protein in the synovial tissues and fluids of patients with RA and its association with inflammation and disease activity (6). Altogether, these findings prompted our present study focusing on S100A11 in SLE.

Citovat

CEREZO, L. A., B. SUMOVA, H. HULEJOVA, H. STORKANOVA, Lenka SZCZUKOVÁ, M. TOMCIK, R. BECVAR, K. PAVELKA, J. VENCOVSKY, J. ZAVADA a L. SENOLT. S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology. PISA: CLINICAL & EXPER RHEUMATOLOGY, 2019, roč. 37, č. 2, s. 338-339. ISSN 0392-856X.

@article{1612297,
   author = {Cerezo, L. A. and Sumova, B. and Hulejova, H. and Storkanova, H. and Szczuková, Lenka and Tomcik, M. and Becvar, R. and Pavelka, K. and Vencovsky, J. and Zavada, J. and Senolt, L.},
   article_location = {PISA},
   article_number = {2},
   keywords = {S100A11; mononuclear cells; systemic lupus erythematosus},
   language = {eng},
   issn = {0392-856X},
   journal = {Clinical and Experimental Rheumatology},
   title = {S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals},
   url = {https://www.ncbi.nlm.nih.gov/pubmed/30719969},
   volume = {37},
   year = {2019}
}

TY  - JOUR
ID  - 1612297
AU  - Cerezo, L. A. - Sumova, B. - Hulejova, H. - Storkanova, H. - Szczuková, Lenka - Tomcik, M. - Becvar, R. - Pavelka, K. - Vencovsky, J. - Zavada, J. - Senolt, L.
PY  - 2019
TI  - S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals
JF  - Clinical and Experimental Rheumatology
VL  - 37
IS  - 2
SP  - 338-339
EP  - 338-339
PB  - CLINICAL & EXPER RHEUMATOLOGY
SN  - 0392856X
KW  - S100A11
KW  - mononuclear cells
KW  - systemic lupus erythematosus
UR  - https://www.ncbi.nlm.nih.gov/pubmed/30719969
L2  - https://www.ncbi.nlm.nih.gov/pubmed/30719969
N2  - Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with complex immunological pathogenesis and diverse clinical features, as a consequence of multi-system inflammation (1). Although there has been a significant progress in the management of patients with SLE, there is an unmet need for specific diagnostic or predictive biomarkers for routine clinical use. Certain members of S100 protein family such as S100A8/9 and S100A12 are upregulated in several autoimmune inflammatory disorders, including SLE (2-4), and their potential as diagnostic or prognostic biomarkers is emerging. S100A11 (calgizzarin) is a less known S100 protein that has been extensively studied in cancer (5). Very recently, our group showed an implication of S100A11 in the pathogenesis of rheumatoid arthritis (RA) and thereby its potential role in autoimmune diseases (6). We described a local accumulation of S100A11 protein in the synovial tissues and fluids of patients with RA and its association with inflammation and disease activity (6). Altogether, these findings prompted our present study focusing on S100A11 in SLE.
ER  -

CEREZO, L. A., B. SUMOVA, H. HULEJOVA, H. STORKANOVA, Lenka SZCZUKOVÁ, M. TOMCIK, R. BECVAR, K. PAVELKA, J. VENCOVSKY, J. ZAVADA a L. SENOLT. S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. \textit{Clinical and Experimental Rheumatology}. PISA: CLINICAL \&{}amp; EXPER RHEUMATOLOGY, 2019, roč.~37, č.~2, s.~338-339. ISSN~0392-856X.

Podrobný výpis o publikaci